L. Iglesias

1.1k total citations
36 papers, 775 citations indexed

About

L. Iglesias is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, L. Iglesias has authored 36 papers receiving a total of 775 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 9 papers in Otorhinolaryngology. Recurrent topics in L. Iglesias's work include Head and Neck Cancer Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Diagnosis and Treatment (7 papers). L. Iglesias is often cited by papers focused on Head and Neck Cancer Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Diagnosis and Treatment (7 papers). L. Iglesias collaborates with scholars based in Spain, Germany and Belgium. L. Iglesias's co-authors include Javier Martínez‐Trufero, Santiago Ponce, Ricard Mesı́a, Juan Antonio Vargas, Ana B. Enguita, Juan J. Grau, Enrique Grande, Juan Jesús Cruz, Luis Paz‐Ares and Jon Zugazagoitia and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

L. Iglesias

32 papers receiving 763 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Iglesias Spain	13	408	210	157	149	115	36	775
Amaury Daste France	13	610 1.5×	279 1.3×	129 0.8×	47 0.3×	173 1.5×	66	848
Ellie Maghami United States	17	525 1.3×	396 1.9×	303 1.9×	124 0.8×	457 4.0×	50	1.3k
Krzysztof Misiukiewicz United States	15	307 0.8×	218 1.0×	108 0.7×	73 0.5×	503 4.4×	68	878
M. Frikha Tunisia	13	398 1.0×	175 0.8×	110 0.7×	114 0.8×	294 2.6×	71	724
Christopher Y. Thomas United States	13	366 0.9×	147 0.7×	174 1.1×	105 0.7×	112 1.0×	21	826
A. Psyrri Greece	9	300 0.7×	193 0.9×	186 1.2×	94 0.6×	225 2.0×	23	814
Carlo Resteghini Italy	18	551 1.4×	266 1.3×	157 1.0×	98 0.7×	370 3.2×	73	1.1k
J.L. Geiger United States	16	681 1.7×	243 1.2×	235 1.5×	113 0.8×	526 4.6×	92	1.3k
Roberta Cerutti Italy	18	343 0.8×	154 0.7×	234 1.5×	193 1.3×	22 0.2×	58	988
Abelardo Meneses Mexico	18	470 1.2×	136 0.6×	138 0.9×	147 1.0×	35 0.3×	40	805

Countries citing papers authored by L. Iglesias

Since Specialization

Citations

This map shows the geographic impact of L. Iglesias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Iglesias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Iglesias more than expected).

Fields of papers citing papers by L. Iglesias

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Iglesias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Iglesias. The network helps show where L. Iglesias may publish in the future.

Co-authorship network of co-authors of L. Iglesias

This figure shows the co-authorship network connecting the top 25 collaborators of L. Iglesias. A scholar is included among the top collaborators of L. Iglesias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Iglesias. L. Iglesias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Losa, Ferrán, Isaura Fernández, L. Iglesias, et al.. (2022). SEOM—GECOD clinical guideline for unknown primary cancer (2021). Clinical & Translational Oncology. 24(4). 681–692. 5 indexed citations

Falco, Agustín, Thiago Bueno de Oliveira, Jon Cacicedo, et al.. (2021). Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice. Cancer Management and Research. Volume 13. 6689–6703. 6 indexed citations

Mesı́a, Ricard, L. Iglesias, J. Lambea, et al.. (2021). Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clinical & Translational Oncology. 23(5). 1001–1001. 2 indexed citations

Fernández-Mateos, Javier, Ricard Mesı́a, Jordi Rubió‐Casadevall, et al.. (2020). Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial. Scientific Reports. 10(1). 16634–16634. 12 indexed citations

Agulló-Ortuño, M. Teresa, Inmaculada García‐Ruiz, C. Vanesa Díaz-García, et al.. (2019). Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology. 85(3). 525–535. 14 indexed citations

Agulló-Ortuño, M. Teresa, Santiago Ponce, L. Iglesias, et al.. (2019). Blood Predictive Biomarkers for Patients With Non–small-cell Lung Cancer Associated With Clinical Response to Nivolumab. Clinical Lung Cancer. 21(1). 75–85. 42 indexed citations

Losa, Ferrán, L. Iglesias, Victòria Fusté, et al.. (2018). 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clinical & Translational Oncology. 20(11). 1361–1372. 30 indexed citations

Matías‐Guiu, Xavier, Victòria Fusté, L. Iglesias, et al.. (2018). Consenso 2018 de la Sociedad Española de Anatomía Patológica y la Sociedad Española de Oncología Médica sobre el diagnóstico y tratamiento del cáncer de origen desconocido. Revista Española de Patología. 52(1). 33–44.

Zugazagoitia, Jon, Daniel Rueda, Ana B. Enguita, et al.. (2017). Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non–Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments. Clinical Lung Cancer. 19(1). 65–73.e7. 8 indexed citations

10.

Zugazagoitia, Jon, Elisabeth Jiménez, Juan Antonio Vargas, et al.. (2017). Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. Frontiers in Medicine. 4. 36–36. 10 indexed citations

11.

Hitt, Ricardo, Ricard Mesı́a, Juan J. Grau, et al.. (2016). Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer (LAUHNC).. Journal of Clinical Oncology. 34(15_suppl). 6001–6001. 17 indexed citations

12.

Balañá, Carmen, Xavier Matías‐Guiu, Darío Rubio-Rodríguez, et al.. (2015). Economic Analysis Of Epicup, An Epigenetic Test To Predict The Tissue Of Origin In Cancer Of Unknown Primary Site, The Usa Payors Perspective. Value in Health. 18(7). A356–A356. 3 indexed citations

13.

Zugazagoitia, Jon, Ana B. Enguita, Juan Antonio Vargas, L. Iglesias, & Santiago Ponce. (2014). The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.. PubMed. 6(Suppl 5). S526–36. 46 indexed citations

14.

Díaz-García, C. Vanesa, Carlos Pérez‐Plasencia, José A. López-Martín, et al.. (2013). DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis. 34(5). 1031–1038. 38 indexed citations

15.

Capdevila, Jaume, L. Iglesias, Irene Halperín, et al.. (2012). Sorafenib in metastatic thyroid cancer. Endocrine Related Cancer. 19(2). 209–216. 92 indexed citations

16.

Berrocal, Alfonso, Pedro Pérez Segura, Carmen Balañá, et al.. (2009). Extended-schedule dose-dense temozolomide in refractory gliomas. Journal of Neuro-Oncology. 96(3). 417–422. 46 indexed citations

17.

Martín, Miguel, Aňa Lluch, Miguel Ángel Seguí, et al.. (2006). Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Annals of Oncology. 17(8). 1205–1212. 156 indexed citations

18.

García‐Alfonso, Pilar, G. Pérez-Manga, M. Carmen González, et al.. (2005). A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (I) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 23(16_suppl). 3540–3540. 1 indexed citations

19.

Rapoport, Bernardo L., Otto Sussmann, F. Schlaeffer, et al.. (1999). Ceftriaxone plus Once Daily Aminoglycoside with Filgrastim for Treatment of Febrile Neutropenia: Early Hospital Discharge vs. Standard In-Patient Care. Chemotherapy. 45(6). 466–476. 20 indexed citations

20.

Iglesias, L., et al.. (1997). UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla Seville, Spain.. PubMed. 11(9 Suppl 10). 74–81. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact